两种阿霉素心力衰竭模型及心功能进展的评估

doi:10.6040/j.issn.1671-7554.0.2020.0781

摘要/Abstract

摘要： 目的评估阿霉素心力衰竭动物模型的建模效果及其在不同实验阶段的心脏结构与功能改变。方法建立大鼠阿霉素心力衰竭动物模型,采用两种造模方法:(1) 阿霉素模型1组为腹腔内注射阿霉素,每次2.5 mg/(kg·只),2周内注射6次,累积剂量15 mg/kg,造模周期为4周;(2) 阿霉素模型2组6周内注射6次,造模周期为8周,其余相同。雄性Wistar大鼠24只,随机分为正常对照1组、阿霉素模型1组、正常对照2组、阿霉素模型2组,每组6只。超声心动图评估心脏结构和功能,苏木素-伊红(HE)染色评估心脏组织结构。结果超声心动图检测结果显示,阿霉素模型1组左室射血分数(LVEF)和左室短轴缩短率(LVFS)较正常对照1组差异有统计学意义(P=0.025,P=0.032)。HE染色2种阿霉素模型均存在细胞肥大、肌纤维纹理走向不规则,心肌细胞胞浆空泡化。评估心肌细胞间质纤维沉积面积,阿霉素模型1组高于正常对照1组(t=4.455,P=0.002),阿霉素模型2组与正常对照2组间差异有统计学意义(t=2.220,P=0.060)。阿霉素模型1组在实验中期、末期阶段心脏结构和功能呈动态改变。在整个实验周期中,心脏扩张明显,心脏左室收缩功能和舒张功能指标如二尖瓣血流速度、二尖瓣环心肌组织动度持续降低。右室功能指标如肺动脉峰流速及速度时间积分呈现先降低后升高的趋势。结论阿霉素模型1组建模成功。在整个实验周期,阿霉素模型1组心脏结构扩张,左室收缩功能和舒张功能持续降低。右室功能呈现实验中期降低、实验末期上调的动态变化。

关键词: 心力衰竭, 阿霉素, 动物模型, 超声心动图

Abstract: Objective To evaluate the effects of two doxorubicin-induced heart failure models and changes of cardiac structure and function at different experiment stages. Methods Two doxorubicin-induced heart failure models were constructed. In the first model, rats received intraperitoneal injection of a cumulative dose of 15 mg/kg doxorubicin 6 times in 2 weeks ［2.5 mg/(kg·rat)］ and the cycle lasted for 4 weeks. In the second model, rats received intraperitoneal injection of a cumulative dose of 15 mg/kg doxorubicin 6 times in 6 weeks ［2.5 mg/(kg·rat)］ and the cycle lasted for 8 weeks. A total of 24 male Wistar rats were randomly divided into normal control group 1, doxorubicin model group 1, normal control group 2 and doxorubicin model group 2, with 6 rats in each group. Cardiac structure and function were detected using transthoracic echocardiography. Histopathology was evaluated using haematoxylin and eosin(HE)staining. Results Echocardiography showed left ventricular ejection fraction(LVEF)and left ventricular fractional shortening(LVFS)in the doxorubicin model group 1 were significantly lower than those in normal control group 1(P=0.025, P=0.032). Stained with HE, tissue sections showed cardiomyocyte hypertrophy, irregular texture of muscle fibers, and intracellular vacuolation in both models. Doxorubicin model group 1 had significantly increased intercellular collagen deposition than normal control group 1(t=4.455, P=0.002), and doxorubicin model group 2 had significantly increased intercellular collagen deposition than normal control group 2(t=2.220, P=0.060). In doxorubicin model group 1, cardiac structure and function showed a dynamic development at the middle and end stages of the cycle. During the whole cycle, the heart obviously dilatated, left ventricular systolic and diastolic functional parameters including mitral flow and movement velocity of mitral valve kept decreasing, while the right ventricular functional parameters, such as pulmonary peak flow velocity and velocity time integral, reduced in the middle stage, but increased in the end stage. Conclusion The first doxorubicin model is successfully establishes. During the whole cycle, cardiac structure dilates, left ventricular systolic and diastolic function continuously worsened, while the right ventricular function decreases in the middle stage but mildly improves in the end stage.

Key words: Heart failure, Doxorubicin, Animal models, Echocardiography

中图分类号:

R541.6+1

张淑莹,武晓峰,郭丽敏,乔温,彭洁琼,李大庆. 两种阿霉素心力衰竭模型及心功能进展的评估[J]. 山东大学学报 (医学版), 2020, 58(12): 1-7.

ZHANG Shuying, WU Xiaofeng, GUO Limin, QIAO Wen, PENG Jieqiong, LI Daqing. Evaluation of two doxorubicin-induced heart failure models and changes of cardiac function[J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 1-7.

参考文献

[1] Park JJ, Choi DJ. Current status of heart failure: global and Korea [J]. Korean J Intern Med, 2020, 35(3): 487-497.
[2] Riehle C, Bauersachs J. Small animal models of heart failure [J]. Cardiovasc Res, 2019, 115(13): 1838-1849.
[3] McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity [J]. Cardiovasc Drugs Ther, 2017, 31(1): 63-75.
[4] Wang Y, Cui X, Wang Y, et al. Protective effect of miR378^* on doxorubicin-induced cardiomyocyte injury via calumenin [J]. J Cell Physiol, 2018, 233(10): 6344-6351.
[5] Rahimi O, Kirby J, Varagic J, et al. Angiotensin-(1-7)reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms [J]. Am J Physiol Heart Circ Physiol, 2020, 318(4): H883-H894.
[6] Bai Y, Chen Q, Sun YP, et al. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with nrf2 upregulation [J]. Cardiovasc Ther, 2017, 35(5). doi: 10.1111/1755-5922.12277.
[7] Carvalho EB, Ramos IPR, Nascimento AFS, et al. Echocardiographic measurements in a preclinical model of chronic chagasic cardiomyopathy in dogs: validation and reproducibility [J]. Front Cell Infect Microbiol, 2019, 9: 332. doi: 10.3389/fcimb.2019.00332.
[8] Gevaert AB, Shakeri H, Leloup AJ, et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model [J]. Circ Heart Fail, 2017, 10(6): e003806. doi: 10.1161/CIRCHEARTFAILURE.116.003806.
[9] Wu A. Heart failure [J]. Ann Intern Med, 2018, 169(10): 738. doi: 10.7326/AITC201806050.
[10] Bosch L, de Haan JJ, Bastemeijer M, et al. The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis [J]. Heart Fail Rev, 2020. doi: 10.1007/s10741-020-09960-w.
[11] Janssen PML, Elnakish MT. Modeling heart failure in animal models for novel drug discovery and development [J]. Expert Opin Drug Discov, 2019, 14(4): 355-363.
[12] Bacmeister L, Schwarzl M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure [J]. Basic Res Cardiol, 2019, 114(3): 19. doi: 10.1007/s00395-019-0722-5.
[13] Katz MG, Fargnoli AS, Gubara SM, et al. Surgical and physiological challenges in the development of left and right heart failure in rat models [J]. Heart Fail Rev, 2019, 24(5): 759-777.
[14] Brenes-Castro D, Castillo EC, Vázquez-Garza E, et al. Temporal frame of immune cell infiltration during heart failure establishment: lessons from animal models [J]. Int J Mol Sci, 2018, 19(12): 3719. doi: 10.3390/ijms19123719.
[15] 黄明, 熊可, 李霄, 等. 心力衰竭动物模型的研究进展[J]. 天津中医药大学学报, 2019, 38(6): 534-540. HUANG Ming, XIONG Ke, LI Xiao, et al. Advances in animal models of heart failure [J]. Journal of Tianjin University of Traditonal Chinese Medicine, 2019, 38(6): 534-540.
[16] Li X, Xu G, Wei S, et al. Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling [J]. BMC Complement Altern Med, 2019, 19(1): 360. doi: 10.1186/s12906-019-2771-6.
[17] He SF, Jin SY, Wu H, et al. Morphine preconditioning confers cardioprotection in doxorubicin-induced failing rat hearts via ERK/GSK-3β pathway independent of PI3K/Akt [J]. Toxicol Appl Pharmacol, 2015, 288(3): 349-358.
[18] Chan BYH, Roczkowsky A, Cho WJ, et al. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodeling [J]. Cardiovasc Res, 2020, cvaa017. doi: 10.1093/cvr/cvaa017.
[19] Cappetta D, Esposito G, Coppini R, et al. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolicdysfunction [J]. Br J Pharmacol, 2017, 174(21): 3696-3712.
[20] Xia Y, Chen Z, Chen A, et al. LCZ696 improves cardiac function via alleviating drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy [J]. J Mol Cell Cardiol, 2017, 108: 138-148. doi: 10.1016/j.yjmcc.2017.06.003.
[21] Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity [J]. Pharmacol Rev, 2004, 56(2): 185-229.
[22] 吕海辰, 夏云龙. 发展中的肿瘤心脏病学[J]. 中国医刊, 2019, 54(8): 816-819. LU Haichen, XIA Yunlong. Developing oncology cardiology [J]. Chinese Journal of Medicine, 2019, 54(8): 816-819.
[23] Lewis GA, Schelbert EB, Williams SG, et al. Biological phenotypes of heart failure with preserved ejection fraction [J]. J Am Coll Cardiol, 2017, 70(17): 2186-2200.
[24] Corremans R, Adão R, De-Keulenaer GW, et al. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity [J]. Clin Exp Pharmacol Physiol, 2019, 46(3): 204-215.
[25] 于彦, 刘博, 徐惠波, 等. 益气泻肺方对阿霉素诱导心力衰竭大鼠心肌损伤的保护作用机制[J].中华中医药杂志, 2019, 34(5): 2051-2055. YU Yan, LIU Bo, XU Huibo, et al. Protective effect of Yiqi Xiefei formula on myocardial injury in rats with heart failure induced by adriamycin [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2019, 34(5): 2051-2055.
[26] Renu K, V-G_ A, P-B TP, et al. Molecular mechanism of doxorubicin-induced cardiomyopathy-an update [J]. Eur J Pharmacol, 2018, 818: 241-253. doi: 10.1016/j.ejphar.2017.10.043.
[27] Russo M, Guida F, Paparo L, et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity [J]. Eur J Heart Fail, 2019, 21(4): 519-528.
[28] Dhingra R, Guberman M, Rabinovich-Nikitin I, et al. Impaired NF-κB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy [J]. Cardiovasc Res, 2020, 116(6): 1161-1174.

相关文章 15

[1]	申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78.
[2]	贾魁,李治国,程翠婷,李志娟,刘瑞卿. 银杏叶片联合曲美他嗪治疗老年慢性心力衰竭的效果及机制[J]. 山东大学学报 (医学版), 2025, 63(6): 19-26.
[3]	李敬,郝盼盼. 急性心力衰竭患者出入院心率变化与预后相关性[J]. 山东大学学报 (医学版), 2025, 63(4): 75-82.
[4]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[5]	王国云,潘臧钰. 子宫腺肌病动物模型研究进展[J]. 山东大学学报 (医学版), 2022, 60(7): 48-55.
[6]	赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29.
[7]	董雪,赵霞,程子捷,韩毅. 左西孟旦和米力农治疗重症心力衰竭合并肾损伤患者711例的药物经济学评价[J]. 山东大学学报 (医学版), 2022, 60(4): 91-98.
[8]	高燕,朱庆颖,栾明亚,刘科卫. 托伐普坦联合达格列净对心衰大鼠心肌纤维化的影响[J]. 山东大学学报 (医学版), 2022, 60(12): 13-18.
[9]	范晓艳,王元耕,陈泽涛. 黄芪桂枝五物汤治疗心衰的网络药理学机制[J]. 山东大学学报 (医学版), 2022, 60(11): 70-81.
[10]	兰洪涛,贾旭,童洲杰,郑曼,胡伯昂,钟明,张薇,王志浩. 无选择性152例成年慢性心力衰竭患者再入院的危险因素[J]. 山东大学学报 (医学版), 2021, 59(4): 63-69.
[11]	仇静静,吴婷,牟亚魁,崔丽梅,郭文涛,韩锋产,孙岩. 大鼠鼓室硬化建模优化及与纤维连接蛋白高表达的关联[J]. 山东大学学报 (医学版), 2021, 59(1): 22-27.
[12]	张传备,李方,翟春晓,余永明,舒明雷,王艺丹,徐良栋,郝恩魁. 高斯过程模型对慢性心衰患者1年内再入院的风险评估[J]. 山东大学学报 (医学版), 2020, 58(6): 28-33.
[13]	张美玲,孙卉,孙文凯,孟朝暾,邬信芳,高伟,李钦. 鼻腔滴入γ干扰素对变应性鼻炎大鼠外周血Th17/Treg细胞及相关细胞因子的影响[J]. 山东大学学报 (医学版), 2020, 58(1): 13-19.
[14]	刘聪聪,刘洪彬,符江,李雷. 多囊卵巢综合征易感基因dennd1a在斑马鱼模型中的表达特性[J]. 山东大学学报 (医学版), 2019, 57(1): 48-54.
[15]	米传晓,刘军妮,邹承伟,周南南. 血清可溶性肿瘤因子2抑制剂、半乳糖凝集素-3蛋白水平在慢性心衰分级及预后中的应用[J]. 山东大学学报 (医学版), 2019, 57(1): 62-67.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed